Updated May 2022

BD continues to closely monitor COVID-19 developments across the world as well as guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and global health officials. We are working to protect the health and safety of BD employees while also ensuring continued availability of BD’s critical health-preserving, life-saving and diagnostic medical devices during this challenging time.

BD manufactures and sources product from multiple locations around the world. All of our global manufacturing and distribution centers are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity. In countries where local governments have imposed restrictions to minimize the spread of coronavirus, BD facilities continue to operate with measures in place to ensure business continuity and minimize risk of disruption to our customers.

BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary.

BD continues to have sufficient raw material and component inventory for the majority of products considered critical-to-COVID. Where materials or components are deemed at risk, BD activates any number of pre-approved contingency plans, including those for:

•  Increased safety stock and expedited air shipments
•  Seeking alternative suppliers
•  Redeploying raw materials and/or finished goods from other parts of the BD network
•  Placing at-risk products on customer allocation to prevent stockpiling
•  Partnering with our global transportation providers and port authorities to move product through alternate routes.

For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation.

BD continues to follow all state, local and federal requirements and ensure adherence to work site health and safety regulations for our essential workers. We have instituted preventative measures at our facilities to help protect employees in accordance with the CDC and government regulations. We will continue to adjust safety protocols in line with these regulations and new science emerging about virus transmission and vaccine effectiveness.

As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to detect SARS-CoV-2, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Specifically, BD:

• Is collaborating with the U.S. government on the development of COVID-19 combination diagnostic tests for core labs, hospitals and point-of-care locations.
• Developed a new, rapid self-test to make COVID-19 testing faster and easier for people to complete in the privacy and safety of their own home.
• Increased manufacturing capacity in Nebraska to support U.S. vaccination agility and preparedness by providing the U.S. government with priority access to hundreds of millions of needles and syringes.
• Committed more than 2 billion needles and syringes to support global COVID-19 vaccination planning efforts in more than 40 countries and delivered shipments of more than 1 billion injection devices around the world.
• Partnered with USA Swimming to provide COVID-19 screening for the Olympic Trials and other competitive swimming events.
• Announced, along with CerTest Biotec, the VIASURE SARS-CoV-2 (N1 + N2) real time PCR detection kit for the BD MAX™ Molecular Diagnostic System that can now be run on saliva specimens.
• Partnered with USA Track & Field to provide rapid COVID-19 testing to enhance athlete safety at track & field events.
• Received Emergency Use Authorization for asymptomatic screening for SARS-CoV-2 through serial rapid antigen testing.
• Launched a rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test.

In addition, BD and the BD Foundation has provided approximately $2.8 million in philanthropic support to help nearly a dozen of its trusted non-profit partners protect vulnerable communities during the COVID-19 pandemic. The majority of these social investments support healthcare workers in the United States, Europe, Latin America, China and India. BD volunteers also responded to the COVID-19 pandemic. Clinically-trained associates in BD sites around the world volunteered their time to augment hospital staff in communities hard-hit by COVID-19; and BD associates from a broad range of disciplines delivered virtual trainings to teach community and non-profit organizations how to contain its spread.